JP2009504654A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009504654A5 JP2009504654A5 JP2008526124A JP2008526124A JP2009504654A5 JP 2009504654 A5 JP2009504654 A5 JP 2009504654A5 JP 2008526124 A JP2008526124 A JP 2008526124A JP 2008526124 A JP2008526124 A JP 2008526124A JP 2009504654 A5 JP2009504654 A5 JP 2009504654A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- yellow fever
- chimeric flavivirus
- fever virus
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70703805P | 2005-08-10 | 2005-08-10 | |
| US60/707,038 | 2005-08-10 | ||
| US71944805P | 2005-09-22 | 2005-09-22 | |
| US60/719,448 | 2005-09-22 | ||
| PCT/US2006/030846 WO2007021672A2 (en) | 2005-08-10 | 2006-08-09 | Vaccination against dengue virus infection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009504654A JP2009504654A (ja) | 2009-02-05 |
| JP2009504654A5 true JP2009504654A5 (enExample) | 2010-08-19 |
| JP5227172B2 JP5227172B2 (ja) | 2013-07-03 |
Family
ID=37758084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008526124A Expired - Fee Related JP5227172B2 (ja) | 2005-08-10 | 2006-08-09 | デングウイルス感染に対するワクチン接種 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080193477A1 (enExample) |
| EP (1) | EP1924280A4 (enExample) |
| JP (1) | JP5227172B2 (enExample) |
| AR (1) | AR055603A1 (enExample) |
| AU (1) | AU2006280144B2 (enExample) |
| BR (1) | BRPI0614265A2 (enExample) |
| CA (1) | CA2618783A1 (enExample) |
| IL (1) | IL189329A (enExample) |
| MY (1) | MY151051A (enExample) |
| NO (1) | NO20081127L (enExample) |
| TW (1) | TW200740458A (enExample) |
| WO (1) | WO2007021672A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2903605A1 (fr) * | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
| FR2906724B1 (fr) * | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
| FR2909286B1 (fr) * | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
| US9211323B2 (en) | 2009-06-01 | 2015-12-15 | Takeda Vaccines, Inc. | Compositions and methods for administration of vaccines against dengue virus |
| US8968996B2 (en) * | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
| BRPI0904020B8 (pt) | 2009-10-01 | 2021-05-25 | Fundacao Oswaldo Cruz | composição vacinal contra o vírus da dengue, e, kit |
| US9821050B2 (en) | 2012-04-02 | 2017-11-21 | The University Of North Carolina At Chapel Hill | Chimeric dengue virus E glycoproteins comprising mutant domain I and domain II hinge regions |
| CA2878599A1 (en) | 2012-07-24 | 2014-01-30 | Jiansheng Yao | Vaccine compositions for prevention against dengue virus infection |
| MY168959A (en) | 2012-07-24 | 2019-01-28 | Sanofi Pasteur | Vaccine compositions for the prevention of dengue virus infection |
| BR112015012515B1 (pt) | 2012-11-30 | 2023-04-11 | Sanofi Pasteur | Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola |
| JP2016504315A (ja) * | 2012-12-14 | 2016-02-12 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | 三価デングウイルス製剤に関する組成物、投与方法および使用 |
| CA3177572C (en) | 2013-03-15 | 2026-02-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for dengue virus chimeric constructs in vaccines |
| SG10201807826XA (en) * | 2014-02-11 | 2018-10-30 | Massachusetts Inst Technology | Novel full spectrum anti-dengue antibody |
| KR20230154072A (ko) | 2014-09-26 | 2023-11-07 | 세퀴러스 유케이 리미티드 | 면역손상된 대상체의 백신 접종 |
| GB201704126D0 (en) * | 2017-03-15 | 2017-04-26 | Blom Nihlén Kim Andrea | Vaccine |
| US11268071B2 (en) | 2017-03-30 | 2022-03-08 | Merck Sharp And Dohme Corp. | Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids |
| AU2018346724B2 (en) | 2017-10-05 | 2025-01-09 | Sanofi Pasteur | Compositions for booster vaccination against dengue |
| CN112912106A (zh) | 2018-09-05 | 2021-06-04 | 武田疫苗股份有限公司 | 登革热疫苗单位剂量及其施用 |
| MX2022001742A (es) | 2019-08-16 | 2022-04-07 | Takeda Vaccines Inc | Metodos para prevenir el dengue y la hepatitis a. |
| EP4110381A1 (en) | 2020-02-27 | 2023-01-04 | Takeda Vaccines, Inc. | Method for removing host cell dna from virus preparation |
| WO2023147342A2 (en) | 2022-01-25 | 2023-08-03 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
| WO2023158989A1 (en) | 2022-02-15 | 2023-08-24 | Takeda Vaccines, Inc. | Dengue vaccine batch mixing process |
| EP4519847A1 (en) | 2022-05-04 | 2025-03-12 | Takeda Vaccines, Inc. | Computer-based determination of flavivirus infectivity |
| CN120225693A (zh) | 2022-11-18 | 2025-06-27 | 武田疫苗股份有限公司 | 测定制剂中具有包含至少一个减毒基因座的核苷酸序列的活减毒黄病毒的比例的方法 |
| CN120529951A (zh) | 2022-11-29 | 2025-08-22 | 武田疫苗股份有限公司 | 大规模黄病毒疫苗生产和制造 |
| WO2025072259A1 (en) | 2023-09-25 | 2025-04-03 | Takeda Vaccines, Inc. | Coadministration of tetravalent dengue vaccine with hpv vaccine |
| WO2025122855A1 (en) | 2023-12-08 | 2025-06-12 | Takeda Vaccines, Inc. | A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6676936B1 (en) * | 1988-07-14 | 2004-01-13 | The United States Of America As Represented By The Department Of Health And Human Services. | Chimeric and/or growth-restricted flaviviruses |
| US6184024B1 (en) * | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
| US5605793A (en) * | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6962708B1 (en) * | 1997-02-28 | 2005-11-08 | Acambis, Inc. | Chimeric flavivirus vaccines |
| US7192593B2 (en) * | 1997-05-23 | 2007-03-20 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens |
| US6541011B2 (en) * | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
| AU1813901A (en) * | 1999-12-01 | 2001-06-12 | Oravax, Inc | Chimeric flavivirus vaccines |
| AU2003239932A1 (en) * | 2002-05-31 | 2003-12-19 | Acambis, Inc. | Tetravalent dengue vaccines |
| US6966281B1 (en) * | 2004-05-05 | 2005-11-22 | Hale James R | Internal combustion device and methods of use |
| FR2903605A1 (fr) * | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
| FR2906724B1 (fr) * | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
| FR2909286B1 (fr) * | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
-
2006
- 2006-08-09 EP EP06800943A patent/EP1924280A4/en not_active Ceased
- 2006-08-09 JP JP2008526124A patent/JP5227172B2/ja not_active Expired - Fee Related
- 2006-08-09 US US12/063,365 patent/US20080193477A1/en not_active Abandoned
- 2006-08-09 BR BRPI0614265-6A patent/BRPI0614265A2/pt not_active Application Discontinuation
- 2006-08-09 WO PCT/US2006/030846 patent/WO2007021672A2/en not_active Ceased
- 2006-08-09 CA CA002618783A patent/CA2618783A1/en not_active Abandoned
- 2006-08-09 AU AU2006280144A patent/AU2006280144B2/en not_active Ceased
- 2006-08-10 TW TW095129386A patent/TW200740458A/zh unknown
- 2006-08-10 MY MYPI20063881 patent/MY151051A/en unknown
- 2006-08-10 AR ARP060103502A patent/AR055603A1/es unknown
-
2008
- 2008-02-06 IL IL189329A patent/IL189329A/en not_active IP Right Cessation
- 2008-03-04 NO NO20081127A patent/NO20081127L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Martinez-Flores et al. | SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants | |
| Khetarpal et al. | Dengue fever: causes, complications, and vaccine strategies | |
| JP6830118B2 (ja) | ワクチン組成物 | |
| JP5227172B2 (ja) | デングウイルス感染に対するワクチン接種 | |
| JP2013542224A5 (enExample) | ||
| ES2337893T3 (es) | Vacuna del virus del nilo occidental. | |
| JP2008529558A5 (enExample) | ||
| JP2008530245A5 (enExample) | ||
| JP6943908B2 (ja) | 迅速かつ持続的な免疫学的治療法 | |
| ATE526411T1 (de) | Avirulente, immunogene flavivirus-chimäre | |
| AU2017297608A1 (en) | Compositions and methods for flavivirus vaccination | |
| Zingaretti et al. | Why is it so difficult to develop a hepatitis C virus preventive vaccine? | |
| AU2022205163B2 (en) | Hepatitis B immunisation regimen and compositions | |
| JP2023518340A5 (enExample) | ||
| Takei et al. | Oral administration of genetically modified Bifidobacterium displaying HCV-NS3 multi-epitope fusion protein could induce an HCV-NS3-specific systemic immune response in mice | |
| JP2010506926A5 (enExample) | ||
| Chen et al. | Advances and perspectives in the development of vaccines against highly pathogenic bunyaviruses | |
| Valiakos et al. | West Nile virus: Basic principles, replication mechanism, immune response and important genetic determinants of virulence | |
| CN116348101A (zh) | 嵌合腺病毒载体 | |
| Kieny et al. | Research and development of new vaccines against infectious diseases | |
| ES2644801T3 (es) | Antígenos de vacuna quimérica contra el virus de la hepatitis c | |
| ES2637629T3 (es) | Inducción de una respuesta inmunitaria frente al virus del dengue usando un enfoque de sensibilización-refuerzo | |
| Sanicas et al. | A review of COVID-19 vaccines in development: 6 months into the pandemic | |
| TW200509964A (en) | VP1 of foot-and-mouth disease virus | |
| US10160979B2 (en) | Pharmaceutical composition for treatment and/or prevention of hepatitis C |